Canada questions safety of Nexium, Prilosec

Health Canada says it's reviewing new safety data on AstraZeneca's heartburn drugs Nexium and Prilosec. The preliminary data shows patients may have had more heart attacks and other cardiac problems than did patients who treated their digestive problems with surgery. The FDA, however, says its review of the data found no increased risk of heart problems. Nexium is AstraZeneca's best-selling drug, with worldwide sales of $1.3 billion during the second quarter of 2007.

- check out this article

Suggested Articles

AstraZeneca and Brazil have expanded their deal for a possible COVID-19 vaccine, this time to the tune of $360 million.

Novavax expects to churn out enough vaccines in 2021 to meet U.S. demand; experts slam the medical and political risks of Russia's unproven vaccine.

Novavax will have billions of doses of COVID-19 vaccine capacity next year and could single-handedly meet U.S. demand, executives said.